462 related articles for article (PubMed ID: 18172063)
1. Midbrain iron content in early Parkinson disease: a potential biomarker of disease status.
Martin WR; Wieler M; Gee M
Neurology; 2008 Apr; 70(16 Pt 2):1411-7. PubMed ID: 18172063
[TBL] [Abstract][Full Text] [Related]
2. Longitudinal midbrain changes in early Parkinson's disease: iron content estimated from R2*/MRI.
Wieler M; Gee M; Martin WR
Parkinsonism Relat Disord; 2015 Mar; 21(3):179-83. PubMed ID: 25534153
[TBL] [Abstract][Full Text] [Related]
3. Quantitative estimation of regional brain iron with magnetic resonance imaging.
Martin WR
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S215-8. PubMed ID: 20082994
[TBL] [Abstract][Full Text] [Related]
4. Assessment of brain iron and neuronal integrity in patients with Parkinson's disease using novel MRI contrasts.
Michaeli S; Oz G; Sorce DJ; Garwood M; Ugurbil K; Majestic S; Tuite P
Mov Disord; 2007 Feb; 22(3):334-40. PubMed ID: 17149719
[TBL] [Abstract][Full Text] [Related]
5. T2-weighted MRI in Parkinson's disease; substantia nigra pars compacta hypointensity correlates with the clinical scores.
Atasoy HT; Nuyan O; Tunc T; Yorubulut M; Unal AE; Inan LE
Neurol India; 2004 Sep; 52(3):332-7. PubMed ID: 15472421
[TBL] [Abstract][Full Text] [Related]
6. MRI assessment of basal ganglia iron deposition in Parkinson's disease.
Wallis LI; Paley MN; Graham JM; Grünewald RA; Wignall EL; Joy HM; Griffiths PD
J Magn Reson Imaging; 2008 Nov; 28(5):1061-7. PubMed ID: 18972346
[TBL] [Abstract][Full Text] [Related]
7. Quantitative assessment of iron deposition in the midbrain using 3D-enhanced T2 star weighted angiography (ESWAN): a preliminary cross-sectional study of 20 Parkinson's disease patients.
Wang C; Fan G; Xu K; Wang S
Magn Reson Imaging; 2013 Sep; 31(7):1068-73. PubMed ID: 23746648
[TBL] [Abstract][Full Text] [Related]
8. Structural changes in the midbrain with aging and Parkinson's disease: an MRI study.
Sohmiya M; Tanaka M; Aihara Y; Okamoto K
Neurobiol Aging; 2004 Apr; 25(4):449-53. PubMed ID: 15013565
[TBL] [Abstract][Full Text] [Related]
9. [MRI in Parkinson's disease and vascular parkinsonism--study on the lesion of substantia nigra].
Aotsuka A; Shinotoh H; Hirayama K; Ikehira H; Fukuda H
Rinsho Shinkeigaku; 1991 Jun; 31(6):619-24. PubMed ID: 1934776
[TBL] [Abstract][Full Text] [Related]
10. Imaging brain iron and diffusion patterns: a follow-up study of Parkinson's disease in the initial stages.
Rossi ME; Ruottinen H; Saunamäki T; Elovaara I; Dastidar P
Acad Radiol; 2014 Jan; 21(1):64-71. PubMed ID: 24331266
[TBL] [Abstract][Full Text] [Related]
11. Neuromelanin magnetic resonance imaging of nigral volume loss in patients with Parkinson's disease.
Kashihara K; Shinya T; Higaki F
J Clin Neurosci; 2011 Aug; 18(8):1093-6. PubMed ID: 21719292
[TBL] [Abstract][Full Text] [Related]
12. Characterizing iron deposition in Parkinson's disease using susceptibility-weighted imaging: an in vivo MR study.
Zhang J; Zhang Y; Wang J; Cai P; Luo C; Qian Z; Dai Y; Feng H
Brain Res; 2010 May; 1330():124-30. PubMed ID: 20303339
[TBL] [Abstract][Full Text] [Related]
13. Magnetic resonance relaxometry in Parkinson's disease.
Mondino F; Filippi P; Magliola U; Duca S
Neurol Sci; 2002 Sep; 23 Suppl 2():S87-8. PubMed ID: 12548357
[TBL] [Abstract][Full Text] [Related]
14. Basal ganglia iron content in Parkinson's disease measured with magnetic resonance.
Ye FQ; Allen PS; Martin WR
Mov Disord; 1996 May; 11(3):243-9. PubMed ID: 8723139
[TBL] [Abstract][Full Text] [Related]
15. Quantitative 1H magnetic resonance spectroscopy and MRI of Parkinson's disease.
O'Neill J; Schuff N; Marks WJ; Feiwell R; Aminoff MJ; Weiner MW
Mov Disord; 2002 Sep; 17(5):917-27. PubMed ID: 12360540
[TBL] [Abstract][Full Text] [Related]
16. Decreased serum ceruloplasmin levels characteristically aggravate nigral iron deposition in Parkinson's disease.
Jin L; Wang J; Zhao L; Jin H; Fei G; Zhang Y; Zeng M; Zhong C
Brain; 2011 Jan; 134(Pt 1):50-8. PubMed ID: 21109502
[TBL] [Abstract][Full Text] [Related]
17. Freezing of gait in early Parkinson's disease: Nigral iron content estimated from magnetic resonance imaging.
Wieler M; Gee M; Camicioli R; Martin WR
J Neurol Sci; 2016 Feb; 361():87-91. PubMed ID: 26810522
[TBL] [Abstract][Full Text] [Related]
18. Quantitative susceptibility mapping of the midbrain in Parkinson's disease.
Du G; Liu T; Lewis MM; Kong L; Wang Y; Connor J; Mailman RB; Huang X
Mov Disord; 2016 Mar; 31(3):317-24. PubMed ID: 26362242
[TBL] [Abstract][Full Text] [Related]
19. Magnetic resonance imaging-based volumetric analysis of basal ganglia nuclei and substantia nigra in patients with Parkinson's disease.
Geng DY; Li YX; Zee CS
Neurosurgery; 2006 Feb; 58(2):256-62; discussion 256-62. PubMed ID: 16462479
[TBL] [Abstract][Full Text] [Related]
20. Changes in substantia nigra and locus coeruleus in patients with early-stage Parkinson's disease using neuromelanin-sensitive MR imaging.
Ohtsuka C; Sasaki M; Konno K; Koide M; Kato K; Takahashi J; Takahashi S; Kudo K; Yamashita F; Terayama Y
Neurosci Lett; 2013 Apr; 541():93-8. PubMed ID: 23428505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
